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Background and objectives: The therapeutic effects of the dopamine D2 receptor (D2R) agonist, bromocriptine, in type 2 diabetes (T2D) have
been attributed to central nervous system actions. However, peripheral dopamine directly modulates glucose uptake in insulin-sensitive tissues
and lipid metabolism in adipose tissue (AT). We hypothesized that the dopaminergic system may be impaired in the adipose tissue of patients with
T2D and that the therapeutic actions of bromocriptine could involve the modulation of metabolism in this tissue.
Methods: The expression of dopamine receptors was evaluated in visceral AT samples from patients with obesity and stratified in several
groups: insulin sensitive (IS); insulin resistance (IR) normoglycaemic; insulin resistant prediabetic; insulin resistant diabetic, according to Ox-
HOMA2IR, fasting glycaemia and HbA1c levels. T2D Goto-Kakizaki rats (GK) were fed a high-caloric diet (HCD) for five months and treated
with bromocriptine (10 mg/kg/day, i.p.) in the last month. The levels of dopaminergic system mediators and markers of insulin sensitivity and
glucose and lipid metabolism were assessed in the peri-epididymal adipose tissue (pEWAT) and brown (BAT) adipose tissues, liver, and skeletal
muscle.
Results: Patients with IR presented a decreasing trend of DRD1 expression in the visceral adipose tissue, being correlated with the expression of
UCP1, PPARA, and insulin receptor (INSR) independently of insulin resistance and body mass index. Although no differences were observed in
DRD2, DRD4 expression was significantly decreased in patients with prediabetes and T2D. In HCD-fed diabetic rats, bromocriptine increased D1R
and tyrosine hydroxylase (TH) levels in pEWAT and the liver. Besides reducing adiposity, bromocriptine restored GLUT4 and PPARg levels in
pEWAT, as well as postprandial InsR activation and postabsorptive activation of lipid oxidation pathways. A reduction of liver fat, GLUT2 levels and
postprandial InsR and AMPK activation in the liver was observed. Increased insulin sensitivity and GLUT4 levels in BAT and an improvement of the
overall metabolic status were observed.
Conclusions: Bromocriptine treatment remodels adipose tissue and the liver dopaminergic system, with increased D1R and TH levels, resulting
in higher insulin sensitivity and catabolic function. Such effects may be involved in bromocriptine therapeutic effects, given the impaired
expression of dopamine receptors in the visceral adipose tissue of IR patients, as well as the correlation of D1R expression with InsR and
metabolic mediators.
 2021 Published by Elsevier GmbH. This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
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Obesity, body mass index (BMI)>30 kg/m2, is a major cause of
morbidity and mortality, associated with an increased risk of metabolic
syndrome and type 2 diabetes (T2D) [1,2]. Moreover, insulin resistance
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metabolism [3]. However, the mechanisms of adipose tissue and liver
insulin resistance are still unknown and under investigation.
The D2 receptor (D2R) agonist, bromocriptine, was approved by the Food
and Drug Administration (FDA) for the treatment of T2D in USA, given
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Abbreviations
AMPK AMP-activated protein kinase
AMPK-Thr172 Phosphorylated AMP-activated protein kinase on 172
threonine residue
BAT Brown adipose tissue
DARPP 32 Dopamine- and cAMP-regulated neuronal
phosphoprotein
DRD1 Gene encoding for human dopamine receptor 1
DRD2 Gene encoding for human dopamine receptor 2
DRD4 Gene encoding for human dopamine receptor 4
D1R Dopamine receptor 1
D2R Dopamine receptor 2
GLUT2 Glucose transporter 2
GLUT4 Glucose transporter 4
HCD High caloric diet
INSR Gene encoding for human insulin receptor
InsR Insulin receptor




T2D Type 2 Diabetes
TH Tyrosine hydroxylase
pEWAT peri-epididymal adipose tissue
PPARA Gene encoding for human peroxisome proliferator-
activated receptor alfa
PPARg Peroxisome proliferator-activated receptor gamma
UCP1 Gene encoding for human uncoupling protein 1
VAT Visceral adipose tissue
Original ArticleBromocriptine-QR appears to be a unique insulin sensitizing therapy with
a good safety profile, without risk of weight gain or hypoglycaemia and
with a potential to reduce adverse cardiovascular risk [4,5]. Moreover, it
also presents important pharmacological advantages, such as lower side
effects, safety, tolerability, and good adherence to treatment [5e7].
Bromocriptine acts on pancreatic beta cells to downregulate glucose-
stimulated insulin secretion (GSIS), avoiding long-term beta cell
exhaustion [8]. On the other hand, it also has positive effects on insulin
sensitivity, which have been attributed to the regulation of the hypo-
thalamic sympathetic output and prolactin secretion [6,9]. Nevertheless,
the existence of functional dopamine receptors in adipose tissue sug-
gests that this drug may exert direct regulatory functions in this tissue
[10]. Although catecholamines have well-known lipolytic effects in the
adipose tissue, recent evidences support the theory that bromocriptine
also acts on adipose tissue to modulate insulin action and glucose and
fatty acid metabolism [11]. Accordingly, we have recently observed that
peripheral dopamine stimulates glucose uptake in vivo in insulin-
sensitive tissues, such as the adipose tissue, liver and skeletal mus-
cle, and bromocriptine directly acts in the same tissues to regulate, not
only glucose uptake, but also insulin sensitivity and metabolic function
[12]. Despite these direct and new effects of bromocriptine that we
described, the effects of chronic bromocriptine stimulation in such tis-
sues have never been addressed before, as well as the role of local
dopaminergic signalling. Therefore, revealing bromocriptine peripheral
actions on insulin-sensitive tissues may enable to identify new thera-
peutic targets and strategies in T2D.
Given the current knowledge of direct dopamine effects in adipose
tissue, in this study, our first objective was to evaluate the expression
of dopamine receptors in the visceral adipose tissue of patients with
metabolic syndrome and correlate it with markers of adipocyte
metabolism. Additionally, our second aim was to investigate the effects
of chronic bromocriptine treatment in an animal model of T2D fed a
hypercaloric diet (HCD) in remodelling adipose tissue dopaminergic
signalling, insulin sensitivity, and metabolic function.
2. RESEARCH DESIGN AND METHODS
2.1. Human study
A cohort of obese patients aged 25e65 years old (diabetic and non-
diabetic) was selected at the obesity surgery appointment at the Hos-
pital Geral de Coimbra (Covões) - Centro Hospitalar Universitário de
Coimbra. All subjects signed an informed consent and the study was
approved by the institutional ethics committee (Ethics Committee of the2 MOLECULAR METABOLISM 51 (2021) 101241  2021 Published by Elsevier GmbH. This isCoimbra University Hospital Centre), according to the principles outlined
in the Declaration of Helsinki. Exclusion criteria were as follows: active
inflammatory and chronic diseases (neurodegenerative diseases or active
tumours), previous restrictive (sleeve gastrectomy) or mal-absorptive
(gastric bypass or duodenal switch) surgeries and T2D medication
other than metformin (GLP-1RA, DPPIV inhibitors or insulin). On the day
before surgery, height and body weight were recorded and fasting blood
samples were collected for biochemical analysis. Visceral white adipose
tissue samples were collected during surgery and kept in liquid nitrogen
to be then stored at - 80 C.
2.2. Patient selection and characterization
Ninety-two obese patients (77 women and 15 men) were divided in
groups according to glycaemic profile: fasting glucose levels, HbA1c,
and Ox-HOMA2IR. Subject characterization resulted in four different
groups: 1 e insulin sensitive group (IS) (n ¼ 17), composed by in-
dividuals that were both IS and normoglycaemic (NG) (Ox-
HOMA2IR < 1); 2 e insulin resistant (IR) and NG group (n ¼ 29), with
insulin resistant patients (Ox-HOMA2IR>1) that were normoglycaemic
(fasting glucose<100 mg/dL and HbA1c<5.7%); 3e prediabetic group
(n ¼ 28), that allocated IR patients with fasting glucose levels from 100
to 125 mg/dL or HbA1c between 5.7 and 6.4%; 4 e T2D group
(n ¼ 18), constituted by IR subjects diagnosed with T2D (fasting blood
glucose>125 mg/dL or HbA1c>6.4%) (Supplementary Table 1) [13].
2.3. RNA extraction
Total RNA was extracted from VAT human biopsies (100 mg) using an
RNeasy Lipid Tissue Mini Kit (Qiagen, Germany). RNA samples were
analysed by NanoDrop One/One spectrophotometer (Thermo Fisher
Scientific, Waltham, MA, USA) at 260 nm to evaluate its concentration.
RNA integrity was also analysed through capillary electrophoresis with
an Agilent RNA 6000 Nano Kit and the results obtained with the Agilent
2100 Bioanalyser (Agilent Technologies, CA, USA).
2.4. Quantitative real-time polymerase chain reaction using the
high throughput platform biomarktm HD system
RNA sample was diluted into the same concentration (25 ng/mL).
Reverse transcriptase enzyme [qScript cDNA super mix (Quanta Bio-
Sciences)] was added to each RNA sample to obtain cDNA. To amplify
cDNA samples, they were mixed with a mix of pooled primers (500 nM
final concentration each), with a PreAmp Master Mix enzyme (Fluid-
igm), following 12 cycles of thermal cycling according to the enzyme
manufacturer. Samples were then treated with Exonuclease I (Newan open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
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England Biolabs) to remove unincorporated primers and were diluted
5  in TE buffer (10 mM TriseHCl, 1 mM EDTA). For each sample a
Pre-Mix was prepared (SsoFast Eva Green Supermix, BioRad), with
DNA binding dye sample reagent at 20  (Fluidigm). Thereafter,
samples were pipetted into the respective inlet of a Fluidigm 96.96
Gene expression IFC. For each gene assay, a mix with 2  Assay
loading reagent (Fluidigm), forward and reverse primers (50 mM stock)
diluted TE buffer was individually prepared. The primers sequences
were: DRD1 forward- ACACAATTAACTCCGTTTCC and reverse-
GTAGTGTCCCTGTTTGATTG; DRD2 forward- TCCACTAAAGGGCAACTG
and reverse- GGAAACTCCCATTAGACTTC; DRD4 forward- CATCTA-
CACTGTCTTCAACG and reverse- ATTAACGTACAAAAGCGCC; UCP-1
forward- ACAGCACCTAGTTTAGGAAG and reverse- CTGTACGCATTA-
TAAGTCCC; PPARA forward- CCTAAAAAGCCTAAGGAAACC and
reverse- GATCTCCACAGCAAATGATAG; and INSR forward- GATC-
CAATCTCAGTGTCTAAC and reverse- CCTTTGAGGCAATAATCCAG, ob-
tained by Sigma Aldrich, (USA) and reconstituted in water to a final
concentration of 100 mM. Then each gene assay was pipetted into their
respective assay inlets on the chip and loaded with the Load mix
(136  ) script of the HX controller (HD Biomark), using the BioMark
HDTM, accordingly to the cycling parameters recommended by Flu-
idigm for 96.96 Gene expression Integrated Fluidic Circuit. Then data
were collected with Data Collection Software and analysed using
Fluidigm Real Time PCR Analysis v2.1 software. All data were
normalized for the reference gene ATCB.
2.5. Animal study
Wistar rats from our breeding colonies (Faculty of Medicine, University
of Coimbra) were kept under standard conditions [13,14]. The
experimental protocol was approved by the local Institutional Animal
Care and Use Committee (ORBEA 04e2015), and all the procedures
were performed by licensed users of Federation of Laboratory Animal
Science Associations (FELASA) and in accordance with the European
Union Directive for Protection of Vertebrates Used for Experimental
and Other Scientific Ends (2010/63/EU). At 1 month of age, type 2
diabetic GK rats were divided into two groups; the first group was
maintained with the same standard diet until 6 months of age (A03;
5% triglycerides and 45% carbohydrates, SAFE, France) (GK group,
n ¼ 33), while the other group was fed a high-caloric diet (HCD) in
the same period (customized A03 HCD with 20% fat plus 20% su-
crose, SAFE, France) to induce weight gain. The HCD-fed group was
randomly divided into three groups: the first group without further
treatment apart from the diet (GKHCD, n ¼ 20), the second group
with bromocriptine treatment in the last month (GKHCDBr, n ¼ 17),
and the third group with vehicle administration during the same
period (GKHCDVh, n ¼ 15). Male Wistar rats fed with a standard diet
for 6 months were used as control (n ¼ 22). Bromocriptine gently
supplied by Generis, (Amadora, Portugal) was diluted 1:4 DMSO/
H2O and administered daily via intraperitoneal (i.p) injection (10 mg/
kg/day) during the last month. In the vehicle group, the same volume
(100 mL) of the vehicle 1:4 DMSO/H2O was administered i.p. during
the same period.
2.6. Insulin tolerance teste
Two days prior to the sacrifice, an intraperitoneal insulin tolerance test
(IPITT) was performed. Fasted (6 h) animals were injected with insulin
(0.25 U/kg, Lilly, Portugal) and glucose was measured before and after
15, 30, 60, and 120 min using a Glucometer (Bayer, Germany). The
area under the curve was then calculated.MOLECULAR METABOLISM 51 (2021) 101241  2021 Published by Elsevier GmbH. This is an open acce
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On the day of the sacrifice, fasting (6 h) glycaemia, triglyceridemia, and
cholesterol levels were measured in the blood sample obtained from
the tail vein by using a Glucometer (Bayer, Germany) and the Accutrend
system (Roche, Germany) with the respective reactive test stipes.
Before sacrifice, the animals were divided into 2 subgroups, those
sacrificed after 6 h fasting e “postabsorptive” (WSD ¼ 15,
GKSD ¼ 21, GKHCD ¼ 13, GKHCDBr ¼ 11, GKHCDVh ¼ 9) and those
sacrificed 1 h after a mixed meal ingestion e “post-prandial”
(WSD ¼ 7, GKSD ¼ 12, GKHCD ¼ 7, GKHCDBr ¼ 6, GKHCDVh ¼ 6).
Then, the animals were anesthetized with ketamine chloride (75 mg/
kg, Nimatek, Dechra, UK) and chlorpromazine chloride (2.65 mg/kg,
Lab. Vitória, Portugal).
In the set of animal sacrificed after 6 h fasting, plasma, and serum
samples were collected by cardiac puncture as previously described
[13,15] for further evaluation of insulin, glucagon, leptin, adiponectin,
and free fatty acid levels. The animals were sacrificed by cervical
displacement, and peri-epididymal adipose tissue (pEWAT), brown
adipose tissue (BAT), muscle, and the liver were collected, weighted
and stored in 4% formalin solution or at 80 C. In the set of animals
sacrificed after a mixed meal, 3 mL of Nutricia, Fortimel (Nestle,
Switzerland) was administered through gavage and animals were
sacrificed 1 h later for tissue collection.
2.8. Western blotting
Tissues were homogenized as previously described [13,14] and
samples were loaded in 8% polyacrylamide gels, separated by SDS-
PAGE and transferred to a PVDF membrane (Advansta, USA). Mem-
branes were incubated with the specific primary antibodies overnight
at 4 C (listed below), and then incubated 2 h at room temperature with
secondary antibodies. The secondary antibodies were anti-mouse (GE
Healthcare, UK), anti-rabbit and anti-goat (Bio-Rad, USA). Membranes
were revealed using ECL substrate in a Versadoc system (Bio-Rad,
USA) and analysed with Image Quant (Molecular Dynamics, USA).
2.9. Reagents, ELISA kits and antibodies
Salts and organic solvents used in solution preparations were purchased
from Thermo Fisher Scientific (Leicestershire, UK), Sigma Chemicals
(United States of America - USA) or Merck Darmstad (Germany), with the
highest grade of purity commercially available. Antibodies used were
AMPK (#2532), AMPK-Thr172 (#2535 GLUT 4, PPARg (#2213S and
#2443S, Cell Signaling, USA), InsRb (sc-57342, Santa Cruz Biotech-
nology, USA), GLUT2 (ab54460) and InsR-Tyr1361 (ab60946, Abcam,
UK). Antibodies D1R, D2R, DARPP32, DARPP32-Thr34 and tyrosine
hydroxylase (TH) were also used (ab81296, ab85367, ab40801 and
ab51114 respectively, Abcam, UK; T1299, Sigma Aldrich, USA). Calnexin
was used as loading control (AB0037, Sicgen, Portugal). Plasma insulin
levels were assessed through the Rat Insulin ELISA Kit, (Mercodia,
Sweden), plasma glucagon using the ELISA Kit (Wako, Germany), and
plasma levels of leptin and adiponectin were measured using the Mouse/
Rat Leptin Quantikine ELISA Kit and Rat Total Adiponectin/Acrp30
Immunoassay (R&D system, USA). Free fatty acids were assessed using
the FFA Assay Kit (ZenBio, NC, USA). Furthermore, 100 mg of liver
samples were homogenised in the lysis buffer (1 mL of 5% NP-40/
ddH2O solution) and hepatic triglycerides content was quantified by the
colorimetric Triglyceride Quantification Assay Kit (Abcam 65336, UK).
Moreover, 30 mg of pEWAT were homogenised in PBS 0.02 M, pH 7.2
(BAM R61, FDA) to quantify b-hydroxybutyrate by a colorimetric assay
(Biovison K632-100, USA).ss article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/). 3
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Non-parametric tests were performed on the clinical human data
(sample size < 30/group), and results were presented as median and
interquartile range. KruskaleWallis and ManneWhitney tests were
used to compare gene expression between groups according to its
division. Spearman correlation test was performed to assess correla-
tion between variables. In the animal study, results were presented as
mean  standard deviation. One-way ANOVA test with Tukey’s mul-
tiple comparisons was used to performed systemic parameters anal-
ysis and total proteins quantification. For phosphorylated proteins,
KruskaleWallis test (all pairwise multiple comparisons) was applied
to determine statistical differences between the groups. DifferencesFigure 1: Expression of dopamine receptor in visceral adipose tissue (VAT) of patien
and DRD4 (C) in each group of patients: insulin-sensitive (IS), and insulin resistant (IR) norm
compared with IS patients for DRD1 (D), DRD2 (E) and DRD4 (F). Bottom line shows the corr
INSR (I). Values are median  interquartile range. KruskaleWallis and ManneWhitney
Spearman’s correlation test was used to performed correlation analysis.
4 MOLECULAR METABOLISM 51 (2021) 101241  2021 Published by Elsevier GmbH. This iswere considered significant at p < 0.05. All computation analyses
were performed using Graphpad Prism (6.0 version, USA).
3. RESULTS
3.1. Expression of dopamine receptors is impaired in the visceral
adipose tissue of patients with insulin resistance
Patients included in the diabetic group (fasting blood glucose>125 mg/
dL or HbA1c>6.4%), were previously shown to have a failure of beta-
cell function, and lower levels of high density lipoprotein cholesterol
and adiponectin, markers of adipose tissue dysfunction [13]. Detailed
clinical characterization of the groups is described in Supplementaryts with metabolic syndrome. Upper line shows VAT expression of DRD1 (A), DRD2 (B)
oglycemic, prediabetic, and type 2 diabetic patients. All IR patients were grouped and
elations between DRD1 expression and UCP-1(G) and PPARA (H) and the insulin receptor
tests were used to analyse gene expression data according to the patient’s group.
an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
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Table 1. Here, we investigated the gene expression of dopamine re-
ceptors in the adipose tissue of these patients and correlated their
expression with markers of adipocyte metabolic function. Expression of
DRD1, DRD2 and DRD4 was evaluated in the four groups of patients,
showing decreased DRD4 expression in patients with prediabetes and
T2D when compared with IS patients (p < 0.05, Figure 1C). No sig-
nificant differences were observed for DRD1 and DRD2 expression
(Figure 1AeC), and no expression was detected for DRD3 and DRD5.
Importantly, DRD1 expression was 10-fold higher than that of the other
dopamine receptors (Figure 1A). In order to evaluate the relation between
insulin resistance (IR) and dopamine receptor expression, all IR patients
(groups 2, 3, and 4) were compared to IS patients, as depicted in
Figure 1 (D, E, F). Decreased DRD4 expression in patients with IR was
also observed when comparing to IS patients (Figure 1F, p < 0.05).
Despite no differences were observed for DRD2 expression, a trend to
decreased DRD1 expression (p ¼ 0.06) was observed in IR patients
when compared to IS individuals. In order to understand the possible
involvement of dopamine receptors in regulating adipocyte metabolism,
the correlation between DRD1 expression with INSR and genes involved
in lipid metabolism was determined. Figure 1 shows a positive corre-
lation between DRD1 expression and UCP-1 (p < 0.001, r ¼ 0.85) (G),
PPARA (p < 0.001, r ¼ 0.55) (H) and INSR expression (p < 0.001,
r ¼ 0.52) (I). Importantly, the expression of UCP-1, PPARA and INSR
was also decreased in diabetic patients, suggesting that the impairment
of adipose tissue dopaminergic signalling is correlated with impaired
insulin sensitivity and metabolic function (data not shown). Multiple
regression analysis has shown that the correlations of D1DR with UCP-1,
PPAR and INSR are independent of IR and BMI (Supplementary Fig. 1).3.2. Bromocriptine treatment increases D1R expression in pEWAT
and the liver in an animal model of T2D and obesity
Although previous evidences indicate the central actions of bromo-
criptine, recent findings suggest a direct action of dopamine and
bromocriptine in peripheral insulin-sensitive tissues [12]. In order to
understand the role of bromocriptine treatment in regulating dopa-
minergic signalling in insulin-sensitive tissues, the protein levels of
D1R, D2R, the downstream effector DARPP32 and tyrosine hydroxylase
(TH) were determined in pEWAT, the liver, BAT and soleus muscle.
Figure 2A shows decreased D1R levels in pEWAT of GK rats feeding a
standard or a HCD (GKHCD) (p< 0.05), similarly to what is observed in
human adipose tissue in Figure 1. Bromocriptine treatment signifi-
cantly improved D1R levels (p< 0.01 vs GKSD and vs GKHCD) to levels
similar to that in Wistar control animals. TH levels were also increased
in treated animals, suggesting higher local dopamine production
(Figure 2C, p < 0.05 vs GK and GKHCD). Similarly, in the liver, D1R
(Figure 2D, p< 0.05 vs GK and GKHCD) and TH levels (2F, p< 0.05 vs
GK, GKHCD and GKHCDVh) were increased after bromocriptine treat-
ment. On the other hand, D2R and DARPP32 levels were not altered
among groups in both tissues (Figure 2B,E, representative western blot
images in the right panel). No significant changes in dopaminergic
receptors and TH levels were observed in BAT and skeletal muscle
(representative western blot images at Figure 2 G and H).3.3. Bromocriptine increases insulin sensitivity and drives
metabolic pathways towards lipid oxidation in pEWAT
In order to understand the impact of dopaminergic system remodelling
induced by bromocriptine in pEWAT, markers for the endocrine and
metabolic function of adipose tissue were evaluated. As shown in
Figure 3, HCD-fed GK rats (GKHCD and GKHCDVh) exhibited increasedMOLECULAR METABOLISM 51 (2021) 101241  2021 Published by Elsevier GmbH. This is an open acce
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compared to GK rats fed a standard diet (GKSD, p < 0.01). Bromo-
criptine significantly decreased epidydimal fat mass (Figure 3B)
(p < 0.05 vs GKHCD and p < 0.01 vs GKHCDVh) and adipocyte size
(Figure 3C) (p< 0.05 vs GKDS, p< 0.0001 vs GKHCD and GKHCDVh).
Representative haematoxylin-eosin images are shown in Figure 3A and
it is clear from the images the effect of bromocriptine in decreasing
adipocyte size. Decreased adiposity in GKHCDBr rats was accompa-
nied by lower plasma leptin levels (Figure 3D, p < 0.001 vs GKHCD
and p < 0.0001 vs GKHCDVh), while adiponectinemia remained un-
changed between groups (Figure 3E) (see Figure 4).
Concerning insulin sensitivity and metabolic pathways, bromocriptine
treatment increased GLUT4 (Figure 3F, p < 0.001 vs WSD, GKSD,
GKHCD and GKHCDVh), insulin receptor (InsR) (Figure 3G, p< 0.001 vs
GKSD and p < 0.0001 vs GKHCD) and PPARy (Figure 3I, p < 0.001 vs
GKSD, p < 0.001 both vs GKHCD and GKHCDVh), while no differences
were observed in total AMPK levels between groups (Figure 3H). The
activation of the InsR and AMPK was determined in postabsorptive and
post-prandial states. In the postabsorptive stage (6 h fasting), no dif-
ferences were found between groups regarding InsR activation (IR-
Tyr1361, Figure 3J). Nevertheless, increased levels of AMPK-Thr172
(Figure 3K, p < 0.05 vs GKSD) and a trend to increase ATP citrate
lyase (ACL-Ser455, Figure 3L, p ¼ 0.056 vs GKSD) were found in
pEWAT after bromocriptine treatment. Such results suggest increased
catabolic activity, and particularly lipid oxidation, which was confirmed
by the increase in b-hydroxybutyrate levels in pEWAT (p < 0.01 vs
WSD, p < 0.001 vs GKSD, p < 0.01 vs GKHCD and p < 0.05 vs
GKHCDVh) by bromocriptine treatment (Figure 3M), while no differ-
ences were found in the serum (data not shown). Increased catabolic
activity is thought to reduce lipotoxicity and IR. Accordingly, in the post-
prandial state, bromocriptine increased IR-Tyr1361 levels (Figure 3N,
p < 0.05 vs GKHCD), while AMPK-Thr172 levels remained similar to
the other groups (Figure 3O).3.4. Bromocriptine reduces liver triglyceride content without
activating liver AMPK pathway
Figure 4A shows liver haematoxylin-eosin staining for the different
studied groups. A high amount of lipid droplets consistent with hepatic
steatosis phenotype was observed in animals fed with a HCD
(Figure 4A, GKHCD and GKHCDVh), consistent with the observed in-
crease in liver weight (Figure 4B, p < 0.001 vs WSD and GKSD) and
triglyceride content (Figure 4C, p < 0.001 vs WSD and GKSD).
Bromocriptine notably reduced the presence of lipid droplets in the
haematoxylin-eosin staining and reversed hepatic steatosis
(Figure 4A), which was accompanied by decreased liver weight
(Figure 4B, p < 0.001 vs GKHCD) and hepatic triglycerides (Figure 4C,
p < 0.01 vs GKHCD and GKHCDVh).
In order to understand the role of bromocriptine in the regulation of
hepatic metabolic function, InsR and AMPK activation, as well as
GLUT2 levels were determined. Animals treated with bromocriptine
showed increased total InsR levels (Figure 4E, p < 0.05 vs GKSD
p < 0.01 vs GKHCD) but no changes in AMPK (Figure 4F). Intriguingly,
lower levels of GLUT2 were also observed after bromocriptine treat-
ment (Figure 4D, p < 0.001 vs WSD, p < 0.01 vs GKSD and p < 0.01
vs both GKHCD and GKHCDVh), as well as lower InsR-Tyr1361
(Figure 4I, p < 0.05 vs GKHCD) and tendentially lower AMPK-
Thr172 levels (Figure 4J, p ¼ 0.07 vs GKSD) in the post-prandial
state. No differences were observed in InsR-Tyr1361 and AMPK-
Thr172 levels in the postabsorptive state (Figure 4G,H).ss article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/). 5
Figure 2: Alterations of dopaminergic signalling in peri-epididymal adipose tissue (pEWAT) and liver after bromocriptine treatment in an animal model of type 2
diabetes and obesity. Increased dopamine D1 receptor (D1R) (A) and tyrosine hydroxylase (TH) (C) in the pEWAT, while no differences were observed for dopamine D2 receptor
(D2R) (B). Similar results were observed for D1R (D), D2R (E) and TH (F) in the liver. Representative western blot images are shown in the right panel. The bottom line shows
representative western blot images from dopaminergic signalling in the brown adipose tissue (BAT) (G) and the skeletal muscle (H), where no differences were found between
groups. Bars represent means  standard deviation. Differences between groups were assessed by one-way ANOVA with Tukey’s multiple comparisons. * Different from WSD; #
different from GKSD; $ different from GKHCD; & different from GKHCDBr. *p < 0,05; **p < 0,01; ***p < 0.001.
Original Article3.5. Bromocriptine increased fasting insulin signalling in brown
adipose tissue but has no effects in the skeletal muscle
Although bromocriptine did not change the BAT dopaminergic system,
increased GLUT4 levels were observed after the treatment (Figure 5A,
p < 0.001 vs WSD, p < 0.01 vs GKSD, p < 0.001 vs GKHCD and
p < 0.05 vs GKHCDVh), while both total levels of IR and AMPK
remained similar between groups (Figure 5B,C). Furthermore,
bromocriptine also increased postabsorptive levels of InsR-Tyr1361
(Figure 5D p < 0.05 vs GKHCD), but not AMPK-Thr172 (Figure 5E).
Animals sacrificed at the post-prandial stage presented similar levels
of InsR-Tyr1361 (Figure 5F) and AMPK-Thr172 (Figure 5G) between
groups. In the skeletal muscle, GLUT4, InsR, and AMPK levels did
not change between groups (Figure 5HeJ). Moreover, either6 MOLECULAR METABOLISM 51 (2021) 101241  2021 Published by Elsevier GmbH. This ispostabsorptive or post-prandial InsR-Tyr1361 and AMPK-Thr172
levels also remained similar between groups (Figure 5KeN).
3.6. Improved adipose tissue insulin sensitivity and metabolic
function after bromocriptine treatment is associated with better
metabolic profile
In accordance with previous reports from our laboratory [16], GK rats
naturally present lower body weight than Wistar rats (Figure 6A and
6A1; p < 0.001). HCD-fed GK rats showed higher weight gain in
the last month (Figure 6B p < 0.05 vs GKSD), which was associated
with increased caloric intake during the same period of time
(Figure 6C p< 0.001, WSD vs GKHCD and GKSD vs GKHCD; p< 0.01
WSD vs and p < 0.001 GKSD vs both GKHCD and GKHCDVh). On thean open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
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Figure 3: Improvement of insulin sensitivity and remodelling of adipose tissue catabolic pathways by Bromocriptine. Haematoxylin-eosin staining (A, 100  ) of peri-
epididymal adipose tissue (pEWAT). Bromocriptine treatment decreased pEWAT weight (B), adipocytes volume (C) and plasma leptin levels (D), while no changes were observed for
plasma adiponectin levels (E). Bromocriptine treatment increased glucose 4 transporter (GLUT4) (F), insulin receptor (InsR) (G) and Peroxisome proliferator-activated receptor
gamma (PPARg, H), while AMP-activated protein kinase (AMPK, I) remained similar between groups. In the bottom panel, no changes were observed in postabsorptive activation of
InsR (InsR-Tyr1361, J), but Bromocriptine increased AMPK-Thr172 (K), ACL-Ser455 (L) and b-hydroxybutyrate levels (M). In the post-prandial stage, the InsR was more activated (,
N), while no differences were found AMPK activation (O) in Bromocriptine-treated rats. Bars show means  standard deviation. One-way ANOVA with Tukey’s multiple comparisons
was used to assess differences between groups. KruskaleWallis test was used to analyse InsR-Tyr1361 and AMPK-Thr172. * Different from WSD; # different from GKSD; $
different from GKHCD; & different from GKHCDBr. Level of significance: *p < 0,05; **p < 0,01; ***p < 0.001.
MOLECULAR METABOLISM 51 (2021) 101241  2021 Published by Elsevier GmbH. This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
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Figure 4: Bromocriptine reduces liver triglycerides content without activating liver AMPK pathway. Liver haematoxylin-eosin staining (A, 100  ) showing a reduction of
hepatic steatosis after bromocriptine treatment, in accordance with lower liver weight (B) and hepatic triglycerides (C). Bromocriptine treatment decreased GLUT2 (D), but increased
InsR (E), while AMPK (F) levels did not alter between groups. No changes were observed in InsR-Tyr1361 (G) nor AMPK-Thr172 (H) in the postabsorptive stage. Postprandially lower
levels of InsR-Tyr1361 (I) and no changes in AMPK-Thr172 (J) were observed. Bars represent means  standard deviation. One-way ANOVA was used for liver weight, hepatic
triglycerides, GLUT2, InsR and AMPK; KruskaleWallis test was used for InsR-Tyr1361 and AMPK-Thr172. *Different from WSD; # different from GKSD; $ different from GKHCD; &
different from GKHCDBr. Level of significance: *p < 0.05; **p < 0.01; ***p < 0.001.
Original Articleother hand, bromocriptine treatment has been shown to prevent
weight gain (Figure 6A2 and 6B, p < 0.001 vs GKHCD and p < 0.05
vs GKHCDVh) and decrease the caloric intake (Figure 6C, p < 0.0001
vs GKHCD and GKHCDVh).
The increased body weight and caloric intake in HCD-fed rats was fol-
lowed by increased fasting plasma triglycerides (Figure 6D, p< 0.0001,
WSD vs GKHCD and p< 0.001 WSD vs GKHCDVh; p< 0.0001, GKSD vs
both GKHCD and GKHCDVh) and total cholesterol levels (Figure 6E
p < 0.0001 WSD vs GKHCD and p < 0.0001 GKSD vs GKHCD).
Interestingly, bromocriptine treatment improved plasma lipid profile by
decreasing both plasma triglycerides (Figure 6D p < 0.001 vs GKHCD
and p< 0.05 vs GKHCDVh) and cholesterol levels (Figure 6E p< 0.001
vs GKHCD), but no significant changes were observed for plasma free
fatty acids (Figure 6F). Such results are in accordance with the lower fat8 MOLECULAR METABOLISM 51 (2021) 101241  2021 Published by Elsevier GmbH. This isaccumulation observed in the liver and pEWAT as well as with increased
pEWAT lipid oxidation, as depicted in Figures 3 and 4.
GK rats are described as a model of glucose intolerance and mild fasting
hyperglycaemia [16], which was now confirmed by increased glycaemia
after 6 h fasting and AUC during the IPITT as presented at Figure 6G,H
respectively (Figure 6G p < 0.0001 WSD vs GKSD; Figure 6H p < 0.05
WSD vs GKSD). The HCD further aggravated such phenotype, by
increasing fasting glycaemia (Figure 6G p< 0.0001 WSD vs GKHCD and
p < 0.001 vs GKHCDVh), AUC during the IPITT (Figure 6H p < 0.0001
WSD vs GKHCD and p < 0.001 vs GKHCDVh) and glycaemia at 1 h
during the IPITT (Figure 6I p< 0.0001 WSD vs GKHCD and p< 0.05 vs
GKHCDVh). Conversely, bromocriptine treatment improved glycaemic
control by decreasing 6 h fasting glycaemia (Figure 6G) in relation to
GKHCD group (p < 0.01) and reducing the difference to Wistar ratsan open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
www.molecularmetabolism.com
Figure 5: Bromocriptine increased fasting insulin signalling in brown adipose tissue but has no effects in the skeletal muscle. Bromocriptine treatment increased levels
of GLUT4 (A) in BAT, while neither InsR (B) nor AMPK (C) levels changed. In the postabsorptive stage increased InsR-Tyr172 (D) after bromocriptine treatment, but no differences
were observed for postabsorptive AMPK-Thr172 (E), nor postprandial InsR-Tyr172 (F) and AMPK-Thr172 (G). In the skeletal muscle, no significant changes were observed for
GLUT4 (H), InsR (I) total AMPK (J), nor InsR and AMPK activation in the postabsorptive (K, L) or postprandial (M and N) stages. Bars represent means  standard deviation. One-way
ANOVA test with Tukey’s multiple comparisons was used to analyse GLUT4, InsR and AMPK total proteins levels; KruskaleWallis test was used for IR-Try1361 and AMPK-Thr172
analyses. * Different from WSD; # different from GKSD; $ different from GKHCD; & different from GKHCDBr. Level of significance: 1 symbol, p < 0.05; 2 symbols, p < 0.01; 3
symbols, p < 0.001.
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Figure 6: Bromocriptine improves metabolic profile in rats. (A) Weight gain curves during the entire period of the study, and specifically in the last month (A1). Bromocriptine
prevented HCD-induced weight gain in the last month (A2 and B). Bromocriptine also reduced caloric intake (C) plasma triglycerides (D) and cholesterol levels (E), without modifying
plasma free fatty acids (F). Glucose homeostasis also improved with bromocriptine treatment, namely fasting glycaemia (G), AUC during the ITT (H) and glycemia at 1 h during the
IPITT (I), despite no differences were observed in plasma insulin (J) and glucagon levels (K). Values are means  standard deviation. Differences between groups were assessed by
one-way ANOVA test with Tukey’s multiple comparisons. * Different from WSD; # different from GKSD; $ different from GKHCD; & different from GKHCDBr. Level of significance: 1
symbol, p < 0.05; 2 symbols, p < 0.01; 3 symbols, p < 0.001.
Original Article(p < 0.05). Moreover, bromocriptine significantly reduced AUC
(Figure 6H, p < 0.001 vs GKHCD) and glycaemia at 1 h during IPITT
(Figure 6I, p< 0.0001 vs GKHCD). Plasma insulin levels were decreased
in GK rats (Figure 6J, p < 0.0001 vs WSD), as consequence of the
described b-cell impairment in this animal model [17,18], and remained
similar in all the GK groups tested (Figure 6J), as well as glucagon
plasma levels (Figure 6K).
4. DISCUSSION
Although the therapeutic effects of the D2R dopaminergic agonist
bromocriptine in T2D have been attributed to central actions, peripheral10 MOLECULAR METABOLISM 51 (2021) 101241  2021 Published by Elsevier GmbH. This isdopamine is acknowledged to directly modulate glucose uptake in
insulin-sensitive tissues and lipid metabolism in white adipose tissue.
Herein, we hypothesized that patients with T2D may have an impairment
of adipose tissue dopaminergic system, which may be a therapeutic
target for bromocriptine in T2D patients. We showed that IR patients
exhibit a downregulation of DRD4 and DRD1 expression in the adipose
tissue, which is correlated with markers of adipocyte metabolic function.
Additionally, we found in an animal model of T2D and HCD-induced
obesity, that bromocriptine remodelled the dopaminergic system of
white adipose tissue and the liver, through increased D1R and TH levels.
Such mechanisms were associated with higher catabolic function,
namely lipid oxidation, and insulin sensitivity in adipose tissue, as well asan open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/)
www.molecularmetabolism.com.
lower hepatic steatosis. Importantly, no effects were observed in skeletal
muscle and BAT, suggesting a predominant action of bromocriptine in
the white adipose tissue.
Borcherding et al., have shown the presence of dopamine receptors in
human adipocytes, specifically in the subcutaneous adipose tissue of
healthy volunteers [10]. Similar to our results, they showed that the D1R
was the most expressed receptor subtype in white adipose tissue, while
dopamine receptors type 2 (D2R and D4R) were the less expressed
[10]. In the present study, no expression of D3R and D5R was observed,
which may be attributed to their absence or very reduced expression or
to technical hints, as the selected primers. Nevertheless, similar ob-
servations were made by Borcherding et al., who also did not find
expression of these two receptors in the subcutaneous adipose tissue
[10]. Importantly, similarly to our findings, the same authors found a
higher expression of D1R in adipocytes than stromovascular fraction
and a 10-fold difference between D1R and D2R expression. In the
present study, we showed for the first time, a dysregulation of dopa-
mine receptors expression in the visceral adipose tissue from patients
with IR and T2D. It is known that dopamine is involved in the regulation
of GSIS, decreasing insulin secretion through D2R-dependent mecha-
nisms [19,20]. It has also been proposed that dopamine-induced
decrease of GSIS could be a protective mechanism to avoid b-cell
exhaustion [8,21]. Accordingly, it has been reported that obese humans
present reduced dopamine levels and/or function, which may be related
to the compensatory hyperinsulinemia usually observed in such patients
[22]. Herein, we show that IR is a condition also characterized by an
imbalance of the dopaminergic system in the adipose tissue, which was
correlated with the downregulation of genes implicated in lipid oxida-
tion, UCP1 and PPARA, as well as with INSR gene. Given that D1R is a
Gs-linked receptor, it is possible that such results reflect lipid oxidation
reduction, which leads to lipotoxicity and IR [9,23]. An interesting
observation is that lower D1R levels were also found in the pEWAT of
T2D rats, confirming the results obtained in human samples and
highlighting a translatability of mechanisms between species.
The D2R dopaminergic agonist bromocriptine is the only dopaminergic
modulator approved for the treatment of T2D, and it is also commonly
used for Parkinson disease and prolactinomas treatment. It was also
shown to have insulin sensitizing and beta-cell protecting effects [4,8,24].
To the best of our knowledge, our study is the first to show that chronic
bromocriptine treatment leads to an increase in D1R protein levels in both
pEWAT and the liver, which may be explained as a possible feedback or
balance between the two dopamine receptor families. Importantly, TH
protein level also increased with bromocriptine treatment. It is possible
that the increased TH levels may reflect increased neuronal dopamine
production within the adipose tissue [25], but questions remain whether
this is caused by the increase of neuronal projections to the adipose
tissue or direct actions of bromocriptine in the tissue. Nevertheless,
increased TH levels suggest increased dopamine synthesis in the adipose
tissue, possibly released by TH-positive neuron terminals or by the adi-
pocytes themselves, which signals through the D1R to regulate adipocyte
metabolism. In fact, the machinery for production of dopamine has been
described to be present in adipocytes [10].
The physiological role of higher dopamine synthesis is not well un-
derstood. However, the predominant expression of D1R, which is
coupled to the Gs protein-cAMP signalling pathway and is further
increased by bromocriptine treatment, suggests that D1R can be
related to the modulation of catabolic pathways in the pEWAT. Indeed,
we have observed increased fasting levels of AMPK-Thr172 and ACL-
Ser455 in pEWAT, suggesting higher fasting catabolic activity, towards
lipid oxidation. This is in accordance with previous results from our
team, showing that the inhibition of D2R by domperidone, whenMOLECULAR METABOLISM 51 (2021) 101241  2021 Published by Elsevier GmbH. This is an open acce
www.molecularmetabolism.comadipose tissue explants were stimulated with dopamine plus insulin,
resulted in acute and marked activation of AMPK, ACL and HSL,
suggesting a stimulatory effect of D1R on lipid catabolism [12].
Bromocriptine also increased the levels of the InsR and GLUT4 in the
pEWAT, as well as the activation of the InsR after the ingestion of a
mixed meal. In adipose tissue explants, activation of D2R was shown
to acutely potentiate insulin-mediated glucose uptake, which may,
nevertheless, denote a role for D2R in the modulation of adipose tissue
glucose uptake following bromocriptine treatment [12].
Increased peripheral metabolism in fat depots result not only in a better
adipose tissue function, but also in the protection of the liver from
lipotoxicity-induced insulin-resistance. Interestingly, herein we found
that although the InsR levels were increased in the liver, its postprandial
activation was reduced, together with lower AMPK activation. Our group
has previously showed that D2R activation by dopamine or bromo-
criptine induce an acute insulin-independent glucose uptake in liver
explants [12]. Here, the observed upregulation of D1R after chronic
bromocriptine treatment may result in the opposite effects. Although the
liver is expected to significantly contribute to glucose uptake upon a
meal ingestion [26], in this study we actually observed lower hepatic
GLUT2 levels. Altogether, our results suggest a metabolic remodelling
towards a higher metabolic activity in the periphery, and particularly in
the white adipose tissue, rather than in the liver, which is consistent
with the dramatic decrease of liver fat and adipose tissue weight/
adipocyte volume. The marked reduction of steatosis is in line with the
observations made by Davis et al. (2006), who also reported lower liver
steatosis after Bromocriptine treatment to obese Zucker rats [27].
Importantly, given that no changes were observed in insulin receptor
and AMPK activation in the liver, the direct effects of dopamine are
questionable. Thus, it is possible that D1R upregulation may be just
implicated in lipid mobilization rather than oxidation in the liver. In the
adipose tissue, reduced lipotoxicity is associated with postprandial in-
sulin sensitivity and glucose uptake, which is in line with the increment
of InsR and GLUT4 levels.
The observed decreased adipose tissue weight is associated with lower
leptin levels, which is in accordance with the work by Borcherding et al.
showing that modulation of D1R decreased leptin levels both in sub-
cutaneous adipose explants and isolated adipocytes [10]. Moreover,
Kok et al., observed decreased plasma leptin levels after bromocriptine
treatment in a cohort of obese women [28].
In the present work, it was also possible to observe a metabolic shift in
the pEWAT of bromocriptine-treated rats, characterized by higher lipid
oxidation rather than glucose utilization in the postabsorptive period and
vice-versa in the post-prandial state. This is physiologically relevant and
shows that bromocriptine restores the balance of energy supply ac-
cording to the energetic status and body energy requirement, which may
be very important for the prevention of lipotoxicity and glucotoxicity, two
hallmarks of insulin resistance and metabolic dysregulation.
Both the BAT and skeletal muscle are considered tissues with higher
metabolic rates, since the majority of disposable post-prandial glucose is
taken up by the skeletal muscle [29] while BAT converts nutrients energy
into chemical energy in the form of heat [30,31]. Both GLUT4 and fasting
InsR-Tyr1361 levels were increased in the BAT of bromocriptine-treated
animals. We previously showed in BAT explants, that dopamine and
bromocriptine exert no direct effects on glucose uptake and InsR and
AMPK activation. Thus, our findings obtained herein in the whole-body
animal model are likely to result from the overall improvement of the
metabolic status and reduction of lipotoxicity, or from other indirect
actions of bromocriptine. On the other hand, the activation of D1R in
skeletal muscle explants was shown to, directly and independently of
insulin, lead to glucose uptake [12]. However, herein no alterations onss article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/). 11
Original Articledopamine receptors and metabolic pathways were found in the skeletal
muscle on the bromocriptine-treated animals. In accordance with the
results found herein that show a lack of effect of bromocriptine in
skeletal muscle, a clinical trial in obese T2D patients reported that
bromocriptine did not improve insulin sensitivity in the skeletal muscle
within the physiologic range of hyperinsulinemia [6,29].
As expected, and in accordance with the increased GLUT4 and InsR
activation in adipose tissues, bromocriptine treatment resulted in
enhanced peripheral insulin sensitivity and improved fasting glycaemia.
Particularly, in the study from Pijl et al. (2010), T2D individuals treated
with bromocriptine for 16 weeks showed lower fasting glycaemia and
improved glucose tolerance tests [32]. Also, bromocriptine treatment in
spontaneous hypertensive rats reduced retroperitoneal body fat, C-
reactive protein, plasma insulin and glucose levels, and HOMA-IR [33].
Some studies have shown that body weight was unaltered in T2D in-
dividuals after bromocriptine administration [28,34,35], which disagrees
with our findings. One factor contributing to the lower body weight in our
animal model could be the decrease in caloric intake. In fact, it has been
shown that bromocriptine treatment restores hypothalamic dopamine
levels in rodents, a mechanism shown to be reduced in hibernating
animals and involved in insulin resistance during such periods [6,36].
Likewise, Davis et al. (2009) described higher hypothalamic D2R levels
after Bromocriptine treatment to obese Zucker rats and associated such
increase with reduced hyperphagia and fat mass [37]. However, we
could not exclude the possibility of a lower caloric intake in
bromocriptine-treated animals due to an improvement in peripheral
metabolism or other unknown peripheral actions. In agreement with
this, we also found an overall improvement in triglyceride and FFA
levels, by diminishing their levels in the liver and their mobilization from
adipose tissue to circulation, effects that were also observed in clinical
trials [38].
5. CONCLUSION
In summary, our results demonstrate the imbalance of dopamine re-
ceptors in visceral adipose tissue from patients with IR, even before
glycaemic dysmetabolism. Lower DRD1 expression correlated with
reduced expression of key markers of adipose tissue metabolic
function and the INSR. Moreover, in an animal model of dysmetabo-
lism, modulation of dopaminergic system through bromocriptine,
restored both D1R and TH in white adipose tissue and the liver. Such
changes were associated with higher activation of catabolic pathways
and lipid oxidation in the adipose tissue during the postabsorptive state
and insulin receptor activation in the postprandial state. Altogether, our
data suggest that the modulation of peripheral dopaminergic system
induces a higher catabolic activity in the white adipose tissue, leading
to mobilization of liver lipids, reduced hepatic and adipose tissue lip-
otoxicity, as well as improved insulin sensitivity and overall metabolic
status. Although additional information on the mechanisms involved on
dopaminergic regulation of glucose and lipid metabolism should be
generated in the future, we can hypothesize that D1R activation could
play a role in enhancing metabolic activity. The disclosure of the
mechanisms involved in bromocriptine therapeutic effects provide new
insights regarding the mechanism of action of bromocriptine in T2D,
and highlight the relevance of the modulation of peripheral dopami-
nergic system for the treatment of metabolic diseases.
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